Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Esther Anyaorah

Registered Nurse Richmond, TX Nurse Practitioner

NPI 1316435860 CMS profile 10824638

12435 Girasole Ct, Richmond, TX 77406

Open in the dashboard

General payments

$6,080

228 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Esther Anyaorah of Richmond, TX is reported in the CMS Open Payments database as having received $6,080 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,612 51
2024 General $1,491 61
2023 General $2,303 83
2022 General $674 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Esther Anyaorah
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Esther Anyaorah were reported at $1,612. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Esther Anyaorah Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $53 $20–$148 $132
2022 $674 $53 $21–$146 $149
2023 $2,303 $84 $26–$196 $160
2024 $1,491 $80 $26–$187 $164
2025 $1,612 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Pharmaceuticals, Inc $1,715 68 payments
  2. Otsuka America Pharmaceutical, Inc. $1,037 37 payments
  3. Alkermes, Inc. $947 34 payments
  4. Teva Pharmaceuticals USA, Inc. $888 34 payments
  5. Neurocrine Biosciences, Inc. $398 16 payments
  6. ITI, Inc. $273 7 payments
  7. AbbVie, Inc. $248 7 payments
  8. Indivior Inc. $189 8 payments
  9. E.R. Squibb & Sons, L.L.C. $104 3 payments
  10. Vanda Pharmaceuticals Inc. $97 4 payments
  11. Other $182 10 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,080 228 payments
Products named General payments · program years 2022–2025
  1. INVEGA SUSTENNA $1,471 59 payments
  2. LYBALVI $947 34 payments
  3. REXULTI $727 25 payments
  4. ARISTADA Cns $596 30 payments
  5. ARISTADA Cns $596 30 payments
  6. ABILIFY MAINTENA $539 21 payments
  7. ABILIFY ASIMTUFII $522 20 payments
  8. ARISTADA Cns $510 26 payments
  9. ARISTADA Cns $510 26 payments
  10. Austedo XR $466 17 payments
  11. Other $3,547 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$54,879

Medicare's payments for the services billed

Medicare patients

118

Average age 51

Services billed

986

43 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Diabetes 42%
Depression 42%
Chronic kidney disease 20%
Arthritis 17%
Heart failure 14%
Alzheimer's or dementia 12%
Ischemic heart disease 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $342
$342 — —
INVEGA
  • Janssen Pharmaceuticals, Inc $188
$188 — —
ARISTADA
  • Alkermes, Inc. $127
$127 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $118
$118 — —
LYBALVI
  • Alkermes, Inc. $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record